Removal of combined antibiotic (florfenicol, tylosin and Tilmicosin (cas 108050-54-0)) during anaerobic digestion and their relative effect
-
Add time:08/21/2019 Source:sciencedirect.com
The relative effect between combined antibiotic and anaerobic digestion (AD) is poorly understood. This study evaluated the effect of antibiotic removal during AD and the combination of florfenicol, tylosin and tilmicosin on the performance of AD and examined the ways in which these antibiotics impact the microbial community. Results showed that at same initial concentration, the removal rates of florfenicol and tylosin under combined antibiotic condition were no less than those under individual antibiotic condition. However, the removal rates of tilmicosin under the combined antibiotic condition were less than those under the single antibiotic condition. Moreover, the combined antibiotic effect on AD was different with individual antibiotics, the combined antibiotic had a marginal negative effect on AD, and methane production increased with the decrease in antibiotic concentration. The combined antibiotics negatively influenced bacterial and archaeal community in AD. Clostridia and Methanomicrobia were the most abundant bacterial and archaeal taxa, respectively.
We also recommend Trading Suppliers and Manufacturers of Tilmicosin (cas 108050-54-0). Pls Click Website Link as below: cas 108050-54-0 suppliers
Prev:Advances in microbial biotechnology of bile acids
Next:Preparation and evaluation of Tilmicosin (cas 108050-54-0) microspheres and lung-targeting studies in rabbits) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Original ResearchEffects of Tilmicosin (cas 108050-54-0) Phosphate Administration on Echocardiographic Parameters in Healthy Donkeys (Equus asinus): An Experimental Study08/29/2019
- Effects of nasal instillation of a nitric oxide-releasing solution or parenteral administration of Tilmicosin (cas 108050-54-0) on the nasopharyngeal microbiota of beef feedlot cattle at high-risk of developing respiratory tract disease08/28/2019
- Astragalus polysaccharides alleviate Tilmicosin (cas 108050-54-0)-induced toxicity in rats by inhibiting oxidative damage and modulating the expressions of HSP70, NF-kB and Nrf2/HO-1 pathway08/27/2019
- ResearchEffects of oral Tilmicosin (cas 108050-54-0) on health and performance in newly received beef heifers08/26/2019
- Microstructure and antioxidative capacity of the microalgae mutant Chlorella PY-ZU1 during Tilmicosin (cas 108050-54-0) removal from wastewater under 15% CO208/25/2019
- Microbiological toxicity of Tilmicosin (cas 108050-54-0) on human colonic microflora in chemostats08/24/2019
- Minimum ignition energy of medicinal powder – Florfenicol and Tilmicosin (cas 108050-54-0)08/23/2019
- Preparation and evaluation of Tilmicosin (cas 108050-54-0) microspheres and lung-targeting studies in rabbits08/22/2019


